Fred Aslan - 15 Feb 2026 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
President and CEO, Director
Signature
/s/ Andrew Cronauer, Attorney-in-Fact
Issuer symbol
ARTV
Transactions as of
15 Feb 2026
Net transactions value
-$58,400
Form type
4
Filing time
18 Feb 2026, 18:48:01 UTC
Previous filing
15 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aslan Fred President and CEO, Director C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO /s/ Andrew Cronauer, Attorney-in-Fact 18 Feb 2026 0001909362

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARTV Common Stock Award $0 +366,850 +30% $0.000000 1,576,798 15 Feb 2026 Direct F1
transaction ARTV Common Stock Tax liability $58,400 -14,600 -0.93% $4.00 1,562,198 15 Feb 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
F2 Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.